Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.
You may also be interested in...
EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension
Europe's scientific advisory committee, the CHMP, gives positive opinions on apixaban and Viropharma's Cinryze, but doesn't want Vectibix's indications extended.
EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension
Europe's scientific advisory committee, the CHMP, gives positive opinions on apixaban and Viropharma's Cinryze, but doesn't want Vectibix's indications extended.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.